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Abstract   
 
Hemostatic abnormalities had been reported in COVID-19 patients, which may include disseminated intravascular 
coagulation (DIC), hypercoagulability, and alterations in platelets parameters. Articles that investigate the alterations of 
hemostatic abnormalities during the COVID-19 disease (2020-2021) and their predictive value of disease outcome 
have been thoroughly reviewed. Among the reviewed articles, thrombocytopenia is observed in 5.0-41.7% of COVID-
19 patients, which is related to disease severity. Moreover, other platelets parameters, including Platelets/lymphocytes 
ratio (PLR), Mean platelets volume (MPV), and aggregation, may also be affected. On the other hand, findings of 
coagulation tests such as D dimer; fibrinogen, Antithrombin (AT), and Fibrin degradation products (FDP) are 
significantly elevated in COVID-19 patients, while in a single study, most of the patients had positive Lupus 
anticoagulants (LA) and normal protein C (PC). In the same perspective, these alterations showed significant 
correlations with disease severity. Overall, hemostatic laboratory markers are significant predictors of COVID-19 
disease outcome as indicated by the increased risk of venous and arterial thrombotic events, especially in ICU 
patients. 
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Background  
Coronavirus disease (COVID-19) was first reported in Wuhan, 
China, in December 2019, then declared by WHO in March 
2020 as a pandemic disease due to its high infectivity and 
worldwide spreading [1]. Among hospitalized patients, the 
mortality rate is about 11.5–13% [2], while 10% of infected 
patients develop severe respiratory symptoms. On the other 
hand, ~80% of patients may be asymptomatic or with mild 
symptoms [3]. Hemostatic alterations had been noted in 
COVID-19 patients, which may include variations in platelets 
count and/or other parameters, Disseminated intravascular 
coagulation (DIC), and hypercoagulability. Patients with a low 
grade of the disease may have normal or increased platelet 
count [4], while critical patients may have thrombocytopenia. 
DIC is demonstrated in 70% of non-survivor patients as 
indicated by raised plasma fibrin degradation products (FDPs) 
and D-Dimer [5]. Also, the reduction in platelets count may 
associates with lung injury leading to pulmonary intravascular 
coagulopathy [6]. In the same perspective, some COVID-19 
patients may develop serious hypercoagulability complications, 
which are associated with the severity of the disease; these 
manifest as thrombotic events in the kidney, lungs, heart, and 
other organs [7]. On the other hand, several studies reported that  
COVID-19 is associated with elevated levels of prothrombin 
time (PT), activated partial thromboplastin time (APTT), and D-
dimer [3], which associates with a greater risk of mortality 
among hospitalized patients [8]. 
 
Alterations in Platelets parameters  
Quantitative and qualitative platelets abnormalities have been 
described in COVID-19 patients, which does not necessarily 
associate with clinical signs, but commonly they showed 
correlations with disease severity. These include 
thrombocytopenia, increased mean platelets volume (MPV), 
and platelets aggregation. 
 
Thrombocytopenia  
Thrombocytopenia is observed in 5.0-41.7 % of COVID-19 
patients with variable degrees, which is reflected by disease 
severity [9,10]. Mild thrombocytopenia (Platelet’s count < 
150x109/l) is detected in 58-95% of COVID-19 cases [11], 
while severe thrombocytopenia (>50x109/l) is rarely observed 
[12]. Thrombocytopenia develops due to the consumption of 
platelets during the course of the infection, as they are observed 
in alveolar sections together with megakaryocytes which is a 
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unique finding of COVID-19 [13]. Moreover, this finding is 
supported by Liu et al., who studied the dynamic alterations in 
thrombocytes among hospitalized patients and claimed that 
inspection of platelets count has an important role in the 
prognosis of the disease [14]. Another quantitative platelet 
parameter evaluated in COVID-19 patients is the 
platelets/lymphocytes ratio (PLR). Yang AP et al. [15] found 
that PLR is increased in COVID-19 patients and could be used 
as a prognostic marker for this disease with specificity and 
sensitivity of 0.44 and 0.77, respectively, and a cutoff value of 
180 [15]. COVID-19 showed an association with Idiopathic 
thrombocytopenic purpura (ITP) in elders as described in a 
systematic review by Bhattacharjee and Banerjee, who reported 
that COVID19–associated ITP cases, 71% were older than 50 
years and had moderate to severe disease [16]. Pseudo 
thrombocytopenia is also reported in some COVID-19 cases 
due to Ethylene diamine tetra acetic acid (EDTA)-dependent 
antibodies. In one report, platelets count was normal at 
admission time, then progressively decreased with aggregated 
platelets in the peripheral blood smear but with no signs of 
bleeding. When performed in a citrated blood sample, platelets 
count return to normal, and the phenomenon disappeared 17 
days later [17].  
 
Mean Platelet Volume  
In addition to thrombocytopenia, COVID-19 seems to affect the 
MPV as reported by Liu et al. study, which revealed that 
thrombocytopenic patients had significantly higher mean 
platelet volume (MPV, median 10.3 fL) than COVID- 19 
patients with retained platelet counts (median 9.9 fL) [5].  
Patients with COVID-19 are associated with increased 
production of large immature platelets as a response of 
megakaryocytes to the increased platelet consumption; 
thereafter, COVID-19 is characterized by greater numbers of 
immature platelets even with normal platelets counts. As 
immature platelets are more functionally active, this could be an 
additional contributing factor for the hypercoagulability 
associated with COVID-19 [18]. Platelet’s parameters and 
COVID-19 disease severity are shown in table 1. 
 
Table 1.  Association of platelets parameters and COVID-19 disease severity 
Marker   Results   Number of 
Patients   




Authors [Ref]  
Platelets/Lymphocytes 
ratio (PLR) 
Increased 93 Patients Significant 
association  
58 Years P < 0.001 Yang AP, et al. [15] 
Thrombocytopenia In mild cases 
<150x109/l) 
In severe cases 
(>50x109/l) 
383 Patients Significant 
association 





41 Patients  No significant 
association 
55 years NA Manne BK, et al. [18] 
Platelets Aggregation Increased 
platelet 
aggregation 
41 Patients Significant 
association 
55 years   P < 0.05 Manne BK, et al. [18] 
 
Platelet’s aggregation  
As mentioned above, reduction in circulating platelets count is 
related to their consumption via intravascular aggregation 
during the formation of pulmonary thrombi. In the same 
perspective and in a recent study, circulating platelets from 
COVID-19 patients showed increased membrane expression of 
P-selectin, a crucial adhesion molecule. Furthermore, platelets 
from COVID-19 patients showed a faster aggregation response 
and increased interaction with collagen and fibrinogen [18]. 
 
Coagulation disturbances  
Significant alterations of coagulation testing had been observed 
in COVID-19 patients. These include elevations of plasma D-
Dimer, Fibrinogen, and FDPs, reduction in plasma level of AT, 
and presence of lupus anticoagulants. These alterations may 
associate with thrombotic events. 
 
D-Dimer and FDPs levels  
Elevated plasma D-dimer levels (> 500ng/ml) are among the 
markers of hypercoagulability associated with COVID-19. 
Furthermore, the elevation of plasma D-Dimer level showed a 
significant correlation with the disease severity [4]. Thus, D- 
 
 
Dimer may serve as a good prognostic marker for identifying 
patients who need critical care [19]. In a retrospective study, a 
multivariate regression test was applied to variables on 
hospitalized COVID-19 patients. Among the tested predictors, 
elevated D-Dimer in addition to other coagulation and 
inflammatory markers at initial presentation were significant 
predictors of coagulation complications (thrombosis or 
bleeding), critical illness, and death [20]. In the same 
perspective, a case-control study showed that elevated D-Dimer 
is a significant predictor of in-hospital mortality with a 
sensitivity of 88.2% and specificity of 71.3% [21]. Plasma 
fibrinogen and its FDPs were also evaluated in COVID-19 
patients. Han et al. reported that plasma levels of fibrinogen and 
FDPs in addition to D-dimer were all elevated significantly 
among COVID-19 patients compared to healthy controls. 
Furthermore, D-dimer and FDP were progressively increased 
with increased disease severity, but the fibrinogen level remains 
static [22].  
 
Anti-thrombin and Lupus anticoagulants  
Anti-thrombin (AT) and protein c (PC) systems are the main 
plasma physiological anticoagulants produced by the liver. 
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Reduction in these coagulation regulators is commonly 
associated with the risk of thrombosis. Evaluation of AT level 
among COVID-19 patients revealed that 55% of cases had AT 
levels below the reference range, while protein C was not 
affected [23]. Another thrombotic risk factor was observed in 
COVID-19, which is the lupus anticoagulants. Bowles et al. 
observed lupus anticoagulants in 91% of COVID-19 patients 
who had prolonged screening APTT [24]. Coagulation tests and 
their association with COVID-19 disease severity in some 
studies are shown in table 2. 
 
Thrombotic disease in COVID-19  
Thrombotic events in hospitalized COVID-19 patients may 
include pulmonary embolism, venous thromboembolic events 
such as proximal deep vein and upper extremity thrombosis, 
and arterial thromboembolic events such as ischemic strokes. 
These thrombotic complications showed an association with the 
severity of the disease; thereafter, they are commonly observed 
in severely ill patients in approximately 25–31% of ICU-
admitted COVID-19 patients [2].  
 
Discussion  
From all the above, hypercoagulability is the most prominent 
hemostatic abnormality encountered in COVID-19 patients [4]. 
It is related to the pro-coagulant effect of the accompanied 
inflammatory status of the disease, which associates with 
increased thrombin generation and involvement of blood 
platelets in the reaction. Widespread inflammatory reaction may 
lead to the systemic prothrombotic status, which is an initiating 
event of acute DIC, while the chronic phase of DIC is 
characterized by hypercoagulability resulting from consumption 
of hemostatic elements, including the platelets [5,6]. 
Among the laboratory markers of hemostatic disturbance, D-
Dimer is consistently elevated in COVID-19 patients 
experiencing hemostatic defects. Moreover, it showed 
significant predictive power for disease severity and mortality 
risk [4,5].  Thereafter, this test could be used as a sensitive and 
specific predictor of hemostatic complications in COVID-19 
patients [19]. Among the other markers, thrombocytopenia is 
another indicator of hemostatic disturbance resulting from 
circulating platelets' consumption during the associated 
prothrombotic status [14]. The degree of thrombocytopenia 
reflects the severity of the hemostatic defect, which in turn is 
related to the severity of the COVID-19 [14, 18]. 
So, in conclusion, COVID-19 patients should have a baseline 
hemostatic profile, including plasma D-Dimer assay and 
platelets count. Then patients with elevated D-Dimer and/or 
thrombocytopenia should be considered at risk of serious 
hemostatic complications and should be managed accordingly.   
 
Conclusion  
Hemostatic disturbances, mainly thrombotic events, were 
reported among COVID-19 patients in association with disease 
severity. Furthermore, hemostatic laboratory markers are 
significant predictors of disease outcome, including critical 
illness and mortality.  
 
Table 2.  Association of elevated D-Dimer and abnormal coagulation tests results with COVID-19 disease severity and mortality   






Markers of severity and 
mortality 
Other findings 





24  4877 ng/ml - All were ICU, intubated 
patients 
- Signs of PE, DVT, and 
severe inflammation 
- Normal PT&APTT 
- Increased Fbg, VWF, FVIII, 
and PC 
Tang N, et al. [5] Brief report 
(Retrospective 
study) 
183 610ng/ml in 
survivors and 2120 in 
non-survivors (p. 
value<.001) 
- The mortality rate is 11.5% 
- DIC in 71.4% of non-
survivors 
-Significantly elevated PT and 
FDPs in non-survivors  





343 >200ng/ml in 67 
patient (20%)  
- 13 in-hospital death.  Elevated D-Dimer >200ng/l 
associated with a higher risk of 
mortality (P<.001; hazard 
ratio51.5, CI 12.9—20.7) 
Al-Samkari H, et 
al. [20] 




-144(36%) critically ill, 
deaths within the 
27(18.75%) 
Thrombosis predicted with high 
D-Dimer [Odd 6.79, 95% CI 
2.39—19.30]  
Yao Y, et al. [21] Original article 
(Case-control 
study) 
248 >200ng/ml in 74.6% 
of cases 
-In-hospital mortality rate 
6.9%   
In-hospital mortality predicted 
with high D-Dimer with a 
sensitivity of 88% and 
specificity of 71.3% 
Han H, et al. [22] Original article 94 Significantly elevated 
in patients compared 
with controls 
(P<0.001) 
-35 (37%) patients with 
severe disease 
-10 (10.6%) patients were 
critically ill 
- Significantly higher Fbg and 
lower AT (P<0.001) in severely 
ill patients compared with mild 
disease 
Bowles L, et al. 
[24] 




35 N.A -Venous thrombosis in 3% 
of cases 
-Prolonged APTT 
-High factor VIII 
- Positive LA in 91% of cases 
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Abbreviation  
APTT: Activated Partial Thromboplastin Time; AT: Anti-
Thrombin; COVID: Corona Virus Disease; DIC: Disseminated 
Intravascular Coagulation; EDTA: Ethylene Diamine Tetra 
Acetic acid; Fbg: Fibrinogen; FDPs: Fibrin Degradation 
Products; ITP: Idiopathic Thrombocytopenic Purpura; LA: 
Lupus anticoagulants; MPV: Mean Platelets Volume; N.A: Not 
applicable, PLR: Platelets Large cell Ratio; PT: Prothrombin 
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